Low avidity antibody: A reliable method to diagnose a recent HIV-1 infection

New Microbiologica

Volumn 31, Issue 1, 2008, Pages 19-26

  Re, Maria Carla ^a,b   Schiavone, Pasqua ^a   Vitone, Francesca ^a   Bon, Isabella ^a   De Crignis, Elisa ^a   Biagetti, Carlo ^a   Alessandrini, Federica ^a   Gibellini, Davide ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Acute infection; Avidity index; HIV 1

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

ACUTE DISEASE; ADULT; ANTIBODY AFFINITY; ARTICLE; BLOOD; EVALUATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MIDDLE AGED; VIROLOGY;

ACUTE DISEASE; ADULT; ANTIBODY AFFINITY; FEMALE; HIV ANTIBODIES; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; MALE; MIDDLE AGED;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 41049112136     PISSN: 11217138     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. ADVANCING HIV PREVENTION. (2003). New strategies for a changing epidemic-United States. MMWR April 18; 52, 329-332.
2. BOURLET T., PRETIS C., PILLET S., LESENECHAL M., PICHE J., POZZETTO B. (2005). Comparative evaluation of the VIDAS HIV DUO Ultra assay for combined detection of HIV-1 antigen and antibodies to HIV. J. Virol Meth. 127, 165-167.
3. BUSCH M.P., SATTEN G.A. (1997). Time course of viremia and antibody seroconversion following human immunodeficiency virus exposure. Am. J. Med. 102, 117-124.
4. CENTERS FOR DISEASE CONTROL. (1989). Interpretation and use of the Western blot assay for serodiagnosis of human immunodeficiency virus type 1 infection. Morb. Mortal. Wkly. Rep. 38, 1.
5. CHAWLA A., MURPHY G., DONNELLY C., BOOTH C.L., JOHNSON M., PARRY J.V., ET AL. (2007). Human immunodeficiency virus (HIV) antibody avidity testing to identify recent infection in newly diagnosed HIV type 1 (HIV-1)-seropositive persons infected with diverse HIV-1 subtypes. J. Clin. Microbiol. 45, 415-420.
6. HASHIDA S., ISHIKAWA S., HASHINAKA K., NISHIKATA I., OKA S., ISHIKAWA E. (2000). Earlier detection of human immunodeficiency virus type 1 p24 antigen and immunoglobulin G and M antibodies to p17 antigen in seroconversion serum panels by immune complex transfer enzyme immunoassays. Clin. Diagn. Lab. Immunol 7, 872-881.
7. HECHT F.M., BUSCH M.P., RAWAL B., WEBB M., ROSENBERG E., SWANSON M., ET AL. (2002) Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 16, 1119-1129.
8. IWEALA O.I. (2004). HIV diagnostic tests: an overview. Contraception 70, 141-147.
9. KASSUTTO S., ROSENBERG E.S. (2004). Primary HIV type 1 infection. Clin. Infect. Dis. 38, 1447-1453.
10. LAZZAROTTO T., GALLI C., PULVIRENTI R., RESCALDANI R., VEZZO R., LA GIOIA A., ET AL. (2001). Evaluation of the Abbott AxSYM cytomegalovirus (CMV) immunoglobulin M (IgM) assay in conjunction with other CMV IgM tests and a CMV IgG avidity assay. Clin. Diagn. Lab. Immunol. 8, 196-198.
11. LE GUILLOU H., LE MEUR A., BOURDON S., RIOU M., LOISON J., FIALAIRE P., ET AL. (2001). Antibody avidity: use for the diagnosis of HIV early infection. Ann. Biol. Clin. 59, 41-47.
12. MCFARLAND W., BUSCH M.P., KELLOGG T.A., RAWAL B.D., SATTEN G.A., KATZ M.H., ET AL. (1999). Detection of early HIV infection and estimation of incidence using a sensitive/less-sensitive enzyme immunoassay testing strategy at anonymous counseling and testing sites in San Francisco. J. Acquir. Immune Defic. Syndr. 22, 484-489.
13. MUBAREKA S., RICHARDS H., GRAY M., TIPPLES G.A. (2007) Evaluation of commercial rubella immunoglobulin g avidity assays. J. Clin. Microbiol. 45, 231-233.
14. TATTEVIN P., CAMUS C., ARVIEUX C., RUFFAULT A., MICHELET C. (2007). Multiple organ failure during primary HIV infection. Clin. Infect. Dis. 44, e28-e29.
15. PUCHHAMMER-STOCKL E., SCHMIED B., RIEGER A., SARCLETTI M., GEIT M., ZANGERLE R., ET AL. (2005) Low proportion of recent human immunodeficiency virus (HIV) infections among newly diagnosed cases of HIV infection as shown by the presence of HIV-specific antibodies of low avidity. J. Clin. Microbiol. 43, 497-498.
16. RE M.C., VITONE F., BON I., SCHIAVONE P., GIBELLINI D. (2006) Meaning of DNA detection during the follow-up of HIV-1 infected patients: a brief review. New Microbiol. 29 (2), 81-88.
17. RIOU M., RENIER G., MATTMAN S., FIALAIRE P., LOISON J., CHENNEBAULT J.M., ET AL. (2000). Dynamic study of anti-HIV antibody avidity after cellular immunity restoration under antiretroviral treatment. Ann. Biol. Clin. 58, 715-720.
18. SCHACKER T.W., HUGHES J.P., SHEA T., COOMBS R.W., COREY L. (1998). Biological and virologic characteristics of primary HIV infection. Ann. Intern. Med. 128, 613-620.
19. SULIGOI B., GALLI C., MASSI M., DI SORA F., SCIANDRA M., PEZZOTTI P., ET AL. (2002). Precision and accuracy of a procedure for detecting recent human immunodeficiency virus infections by calculating the antibody avidity index by an automated immunoassay-based method. J. Clin. Microbiol. 40, 4015-4020.
20. SULIGOI B., MASSI M., GALLI C., SCIANDRA M., DI SORA F., PEZZOTTI P., ET AL. (2003). Identifying recent HIV infections using the avidity index and an automated enzyme immunoassay. J. Acquir. Immune Defic. Syndr. 32, 424-428.
21. THOMAS H.I., WILSON S., O'TOOLE C.M., LISTER C.M., SAEED A.M., WATKINS R.P., ET AL. (1996). Differential maturation of avidity of IgG antibodies to gp41, p24 and p17 following infection with HIV-1. Clin. Exp. Immunol. 103, 185-191.
22. WEBER B., BERGER A., RABENAU H., DOERR H.W. (2002). Evaluation of a new combined antigen and anti-body human immunodeficiency virus screening assay, VIDAS HIV DUO Ultra. J. Clin. Microbiol. 40, 1420-1426.
23. WHO COLLABORATING GROUP ON WESTERN BLOTTING. (1990). Proposed WHO criteria for interpreting results from Western blot assays for HIV-1, HIV-2 and HTLV-I/HTLV-II. Wkly. Epidemiol. Rec. 37, 281-283.
24. WILSON K.M., DI CAMILLO C., DOUGHTY L., DAX E.M. (2006). Humoral immune response to primary rubella virus infection. Clin. Vaccine Immunol. 13, 380-386.
25. WU X., JACKSON S. (2002). Plasma and salivary IgA subclasses and IgM in HIV-1-infected individuals. J. Clin. Immunol 22, 106-115.